FibroBiologics sets CFO salary at $400,000

FibroBiologics, Inc. updated the compensation of its Chief Financial Officer.

Accepted by SEC EDGAR 03/06/2026 - 04:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

FibroBiologics, Inc. updated the compensation of its Chief Financial Officer. On March 4, 2026, the board’s Compensation Committee approved a new annual base salary of $400,000 for CFO Jason D. Davis, effective January 1, 2026. His target for annual non‑equity incentive compensation remains at 40% of base salary.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What compensation change did FibroBiologics (FBLG) make for its CFO?

FibroBiologics increased CFO Jason D. Davis’s annual base salary to $400,000, effective January 1, 2026. His target for annual non-equity incentive compensation remains at 40% of base salary, as approved by the board’s Compensation Committee on March 4, 2026.

When does the new $400,000 salary for FibroBiologics’ CFO take effect?

The new $400,000 annual base salary for FibroBiologics’ CFO Jason D. Davis is effective January 1, 2026. This effective date was approved by the company’s Compensation Committee on March 4, 2026, and applies to his ongoing executive compensation package.

Did FibroBiologics change the CFO’s bonus target percentage?

FibroBiologics did not change the CFO’s bonus target percentage. Jason D. Davis’s target amount for annual non-equity incentive compensation remains at 40% of base salary, even as his base salary was set at $400,000 effective January 1, 2026.

Who approved the new compensation for FibroBiologics’ CFO?

The new compensation for FibroBiologics’ CFO was approved by the Compensation Committee of the Board of Directors. On March 4, 2026, the committee set Jason D. Davis’s annual base salary at $400,000, effective January 1, 2026, with a continued 40% incentive target.

Which executive at FibroBiologics is affected by this 8-K filing?

The 8-K filing concerns Jason D. Davis, the Chief Financial Officer of FibroBiologics, Inc. It documents a change in his compensation, specifically a new annual base salary of $400,000 effective January 1, 2026, with his 40% incentive target unchanged.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000195877700019587772026-03-042026-03-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 04, 2026

FibroBiologics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41934	86-3329066
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
455 E. Medical Center Blvd, Suite 300
Houston, Texas				77598
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 281 671-5150

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value		FBLG		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 4, 2026, the Compensation Committee of the Board of Directors of FibroBiologics, Inc. (the “Company”) approved a new annual base salary of $400,000, effective January 1, 2026, for Jason D. Davis, the Company’s Chief Financial Officer. Mr. Davis’ target amount as a percentage of base salary for annual non-equity incentive compensation remains at 40%.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FibroBiologics, Inc.
Date:	March 6, 2026	By:	/s/ Pete O'Heeron
		Name: Title:	Pete O'Heeron Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB